Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Anika Therapeutics (ANIK) Net Income towards Common Stockholders: 2010-2025

Historic Net Income towards Common Stockholders for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to $846,000.

  • Anika Therapeutics' Net Income towards Common Stockholders rose 103.01% to $846,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.8 million, marking a year-over-year decrease of 56.50%. This contributed to the annual value of -$47.6 million for FY2024, which is 39.97% up from last year.
  • Per Anika Therapeutics' latest filing, its Net Income towards Common Stockholders stood at $846,000 for Q3 2025, which was up 24.96% from $677,000 recorded in Q2 2025.
  • Anika Therapeutics' 5-year Net Income towards Common Stockholders high stood at $16.2 million for Q4 2023, and its period low was -$28.1 million during Q3 2024.
  • Over the past 3 years, Anika Therapeutics' median Net Income towards Common Stockholders value was -$2.6 million (recorded in 2024), while the average stood at -$4.6 million.
  • Examining YoY changes over the last 5 years, Anika Therapeutics' Net Income towards Common Stockholders showed a top increase of 411.38% in 2022 and a maximum decrease of 853.99% in 2022.
  • Quarterly analysis of 5 years shows Anika Therapeutics' Net Income towards Common Stockholders stood at -$3.2 million in 2021, then surged by 411.38% to $10.1 million in 2022, then skyrocketed by 60.71% to $16.2 million in 2023, then plummeted by 219.74% to -$19.4 million in 2024, then skyrocketed by 103.01% to $846,000 in 2025.
  • Its Net Income towards Common Stockholders stands at $846,000 for Q3 2025, versus $677,000 for Q2 2025 and -$915,000 for Q1 2025.